We can unfortunately not supply individual patients with Oxabact, as the drug is not approved on the market. For inquires about development proposals, please Contact us.

Yes, the bacteria are natural inhabitants of the human gastrointestinal tract. However, not everyone is colonized with O. formigenes. Oxalobacter is a Gram-negative bacterium, that is sensitive to antibiotics targeting this group of bacteria. Excessive use of antibiotics has decreased the prevalence of Oxalobacter in the natural flora. Studies have demonstrated the link between increased prevalence of kidney stones and decreased prevalence of Oxalobacter colonization.

Some studies suggest that increasing dietary intake of oxalate together with decreasing intake of dietary calcium has a beneficial effect on the number of Oxalobacter in the gut. However, the therapeutic levels of Oxalobacter needed for treatment hyperoxaluria cannot be sustained by diet alone.

The intention for Oxazyme® is for the treatment of secondary hyperoxaluria, where the reason for hyperoxaluria is increased ingestion or super-absorption of oxalate. Oxazyme® is an enzyme that degrades oxalate from dietary sources. The enzyme acts in the gut. The degradation of oxalate by Oxazyme® prevents oxalate from being absorbed from the gut and into the body.

Oxabact® (Oxalobacter formigenes bacteria) and Oxazyme® (oxalate decarboxylase) act in different ways. While the primary mode of action of Oxabact® is to interact with the intestinal epithelial cells and promote secretion of oxalate from from blood plasma into the gut, Oxazyme® breaks down dietary oxalate in the gut.